This pathway is also deregulated in human epidermal growth factor receptor 2 (HER2)-enriched BC where it is involved in the development of resistance toward anti-HER2 agents, largely due to PIK3CA mutations (Nagata et al., 2004; Berns et al., 2007; Chandarlapaty et al., 2012). Here, ERBB2 is linked to breast cancer.